| Critical Care and Intensive Care Medicine | Lifetime | 15 | NL 1 | 99.72 |
| Epidemiology | Lifetime | 237 | NL 5 | 99.70 |
| Infectious Diseases | Lifetime | 89 | NL 4 | 99.72 |
| Molecular Medicine | Lifetime | 68 | NL 3 | 98.35 |
| Clinical Biochemistry | Lifetime | 136 | NL 6 | 97.57 |
| Applied Microbiology and Biotechnology | Lifetime | 56 | NL 2 | 96.42 |
| Emergency Medicine | Lifetime | 991 | NL 20 | 86.93 |
| Epidemiology | 2021-2025 | 386 | NL 7 | 96.77 |
| Infectious Diseases | 2021-2025 | 564 | NL 13 | 87.52 |
| Molecular Medicine | 2021-2025 | 164 | NL 1 | 70.38 |
| Applied Microbiology and Biotechnology | 2021-2025 | 109 | NL 3 | 71.97 |
| Nosocomial Infections in ICU | Lifetime | 7 | NL 1 | 99.88 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 20 | NL 2 | 99.82 |
| Pneumonia and Respiratory Infections | Lifetime | 32 | NL 3 | 99.78 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 27 | NL 2 | 99.74 |
| Antibiotic Use and Resistance | Lifetime | 27 | NL 2 | 99.70 |
| Antibiotic Resistance in Bacteria | Lifetime | 74 | NL 2 | 99.70 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 40 | NL 2 | 99.49 |
| Healthcare Decision-Making and Restraints | Lifetime | 22 | NL 1 | 99.10 |
| Urinary Tract Infections Management | Lifetime | 150 | NL 3 | 98.75 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 212 | NL 6 | 98.69 |
| Respiratory viral infections research | Lifetime | 328 | NL 11 | 98.68 |
| Emergency and Acute Care Studies | Lifetime | 321 | NL 7 | 98.14 |
| Sepsis Diagnosis and Treatment | Lifetime | 354 | NL 19 | 98.41 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 402 | NL 25 | 97.95 |
| Respiratory Support and Mechanisms | Lifetime | 710 | NL 24 | 98.21 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 529 | NL 19 | 97.64 |
| Streptococcal Infections and Treatments | Lifetime | 419 | NL 16 | 97.63 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 595 | NL 12 | 97.80 |
| Bacterial biofilms and quorum sensing | Lifetime | 464 | NL 19 | 97.44 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 112 | NL 6 | 96.78 |
| Infection Control in Healthcare | Lifetime | 205 | NL 2 | 94.43 |
| Surgical site infection prevention | Lifetime | 630 | NL 21 | 91.72 |
| Immune responses and vaccinations | Lifetime | 855 | NL 48 | 81.66 |
| Inflammation biomarkers and pathways | Lifetime | 970 | NL 31 | 68.12 |
| Historical Medical Research and Treatments | Lifetime | 429 | NL 5 | 70.17 |
| Antibiotic Use and Resistance | 2021-2025 | 572 | NL 12 | 89.93 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 460 | NL 9 | 87.56 |
| Nosocomial Infections in ICU | 2021-2025 | 411 | NL 11 | 80.43 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 779 | NL 22 | 82.10 |
| Immune responses and vaccinations | 2021-2025 | 268 | NL 41 | 78.41 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 932 | NL 28 | 80.74 |
| Urinary Tract Infections Management | 2021-2025 | 798 | NL 22 | 77.65 |
| Surgical site infection prevention | 2021-2025 | 635 | NL 43 | 68.57 |
| Inflammation biomarkers and pathways | 2021-2025 | 384 | NL 10 | 44.67 |
